Algeria HIV Therapeutics Market Analysis Report [2022-30]

Algeria HIV Therapeutics Market Analysis

$ 3999

The Algeria HIV therapeutics market is expected to reach $27.52 Mn by 2030, up from $xx Mn in 2022, with a CAGR of xx% from 2022 to 2030. Local Players such as Opalia Pharma, Biopharm, and Saidal Group dominate the HIV therapeutics market in Algeria. The government policies, funding, and initiatives by international organizations like UNAIDS to manage HIV infections in the country propel the market. The HIV therapeutics market in Algeria is divided into four segments: type, product, geography, end user, and distribution channel.

ID: IN10DZPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Algeria AUTHOR: Dr. Vishwa Modhia

Buy Now

Algeria HIV Therapeutics Market Analysis Summary

Algeria is a country located in Northern Africa bordering the Mediterranean Sea. It is considered the gateway between Africa and Europe. The Algeria HIV therapeutics market is expected to reach $27.52 Mn by 2030, up from $xx Mn in 2022, with a CAGR of xx% from 2022 to 2030.

According to the most recent WHO data published in 2020, the number of HIV/AIDS deaths in Algeria reached 193, accounting for 0.10 % of all deaths. Algeria ranks 126th in the world with an age-adjusted death rate of 0.43 per 100,000 population. Algeria had an adult HIV/AIDS prevalence rate of less than 0.1 % in 2020, with 18,000 HIV cases.

The Algerian government, through its Ministry of Health (MoH), has asked people living with HIV and drug users to avoid visiting hospitals and medical facilities in order to avoid being exposed to COVID-19 infection risks. As part of this preventive strategy, the MoH increased its partnership with local NGOs and collaborated with the UN in Algeria to deliver treatment to people living with HIV and people who use drugs. Algeria spent 6.3% of its GDP on healthcare in 2020.

Market Dynamics

Market Growth Drivers

Several non-governmental organisations (NGOs) such as SOS AIDS Algeria and Association de lutte contre le sida (ALCS) are involved in HIV testing and counselling as well as HIV medication distribution. The United Nations Programme on HIV/AIDS (UNAIDS) UNAIDS is leading efforts to reduce AIDS from a public health threat by 2030. UNAIDS works to raise HIV awareness and reduce stigma in Algeria. As of 2021, 21,000 Algerian adults and children had HIV. Unfortunately, this figure is rising. UNAIDS in Algeria is focusing on the prevention of mother-to-child HIV transmission. It is also investing specifically in programmes that promote education, rights, and leadership for women, girls, and young people. These factors may entice new entrants into the HIV therapeutics market in Algeria.

Market Restraint

Alegria, like any other country, is not perfect; the upper-middle-income country has a poverty rate of 14.6%. This high rate can be attributed to factors such as low healthcare business growth, decreased purchasing power, femicide, and stagnant economic growth. These factors may deter new entrants into the Algerian HIV therapeutics market.

Competitive Landscape

Key Players

Saidal Group (DZA)
Biopharm (DZA)
Opalia Pharma (DZA)
ViiV Healthcare
Bristol Myers Squibb
Merck & Co.
Gilead Sciences

Healthcare Regulations and Reimbursement Policies

In Algeria, the National Agency for Food and Drug Administration and Control (NAFDAC) is in charge of registering, licencing, and regulating all medicines and health products. NAFDAC ensures that HIV therapeutics and other health products meet safety, efficacy, and quality standards before they are approved for use in Algeria. To ensure the safety and quality of HIV therapeutics in Algeria, NAFDAC has implemented a number of regulations.

In Algeria, HIV therapeutics are reimbursed through various public and private health insurance schemes. The National Health Insurance Scheme (NHIS), a government-run health insurance programme, oversees HIV therapeutics reimbursement in the public health system. The National Health Insurance Scheme (NHIS) covers a wide range of health services, including HIV therapeutics, and aims to improve access to healthcare for all Algerians, particularly the poor. The National Insurance Commission (NAICOM) regulates health insurance companies, overseeing their operations and ensuring compliance with industry regulations.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.